Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

AGM Statement

20 Sep 2007 07:01

Angle PLC20 September 2007 For Immediate Release 20 September 2007 ANGLE plc ('ANGLE' or the 'Company') AGM Statement At the Annual General Meeting of ANGLE plc today, Hance Fullerton, retiringChairman, will make the following statement: "ANGLE has made a strong start to the year, continuing to trade in line with theexpectations for the year outlined at our Preliminary Results announcement on 5July. Solid progress has been made in both of our key operating divisions. Our Management services business is now trading profitably and is expected todeliver at least £0.4 million profit for the year. In addition to successfullyimplementing £1m of annualised cost savings, ANGLE has also secured asignificant new contract win with the Innovation Lincolnshire Outreach Programmewhich, as announced on 27 June, will generate £0.9m of revenue for the Companyover a 21 month period. The Group will continue to pursue further such contractsin order to drive revenue growth and broaden its exposure to a pipeline ofpotentially high-value IP opportunities. Solid progress has also been made within our Ventures division. Evidence ofsuccessful value creation has been demonstrated, as announced on 5 July, througha £4 million profit from the gain in fair value of portfolio company Geomerics.Furthermore, in line with our current strategy, operating costs in this divisionhave also been reduced by an estimated £1.3 million on an annualised basis. As previously announced, I am retiring following today's Annual General Meetingand Garth Selvey is succeeding me as non-executive Chairman. I would like tothank the Chief Executive, other directors and senior management for all theirsupport over the years. I look forward to hearing of ANGLE's success in thefuture." Andrew Newland, Chief Executive will add: "I would like to take this opportunity to thank Hance for all his hard work anddedication to ANGLE over the years. Under his stewardship, the Group hasdeveloped from a start-up business to an established leader in IPcommercialisation. We wish Hance all the best for a long and enjoyableretirement and sincerely thank him for his outstanding contribution to ANGLE." Enquiries: ANGLE plc Andrew Newland, Chief Executive 01483 295830Ian Griffiths, Finance Director Collin Stewart Europe Limited 020 7523 8350Mark Connelly Scott Harris 0207 653 0030Stephen Scott, James O'Shaughnessy, Harry Dee Buchanan Communications 0207 466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors Founded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE is listed on AIM (AGL.L); further informationcan be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.